Monash IVF investors are demanding the ASX-listed fertility giant’s management explain an embryo mix-up at its Melbourne laboratory – the second that the company has been forced to disclose in three months.

Shares slumped by more than a quarter on Tuesday after the company said it had transferred the wrong embryo to a patient, taking the share price slide beyond 50 per cent since the first incident was made public in April.